Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile

Clostridium difficile infection (CDI) is a leading nosocomial disease estimated to cause nearly half a million cases in the United States annually. Recurrent CDI (rCDI) affects ~25% of patients after completion of standard of care therapy and is associated with substantial health care costs and a ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Alonso, Carolyn D, Mahoney, Monica V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301304/
https://www.ncbi.nlm.nih.gov/pubmed/30588042
http://dx.doi.org/10.2147/IDR.S159957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301304/
https://www.ncbi.nlm.nih.gov/pubmed/30588042
http://dx.doi.org/10.2147/IDR.S159957

Ejemplares similares